Diabetes drug shows promise for sleep apnea in tiny trial
NCT ID NCT07281196
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This completed study tested whether semaglutide, a drug used for type 2 diabetes and weight loss, could improve sleep apnea in 15 people with diabetes or obesity. Researchers measured breathing pauses during sleep (AHI) after 1 and 4 weeks of treatment. The goal was to see if the drug might offer a new option for managing sleep apnea, but the study was very small and lacked a comparison group.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
semaglutide (a once-weekly injection for diabetes and weight loss)
What this could lead to
If it works, this could point toward a new way to ease sleep apnea symptoms in people with diabetes or obesity.
What could go wrong
This was a very small study (15 people) with no placebo group, so results may not be reliable or apply to everyone. It only looked at short-term effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Shanghai Fengxian District Central Hospital
Shanghai, 201499, China